期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 13, 期 1, 页码 118-127出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.1c00613
关键词
Fructose-1; 6-bisphosphatase; Type 2 diabetes; Allosteric inhibitor; Indole derivatives
资金
- National Natural Science Foundation of China [81502933]
- Beijing Natural Science Foundation [7132138]
- CAMS Initiative for Innovative Medicine [CAMS-I2M-2-004, 2020I2M-1-003]
- Beijing Outstanding Young Scientist Program [BJJWZYJH01201910023028]
A series of new indole and benzofuran analogues were designed and synthesized to evaluate their inhibitory activity against FBPase. Compounds with N-acylsulfonamide moiety on the 3-position of the indole-2-carboxylic acid scaffold showed submicromolar IC50 values, providing insights for creating structurally distinct FBPase inhibitors with high potency and drug-like properties. Three X-ray crystal structures of the complexes were solved, revealing the structural basis for the inhibitory activity.
Liver fructose-1,6-bisphosphatase (FBPase) is a key enzyme in the gluconeogenesis, and its inhibitors are expected to be novel antidiabetic agents. Herein, a series of new indole and benzofuran analogues were designed and synthesized to evaluate the inhibitory activity against FBPase. As a result, the novel FBPase inhibitors bearing N-acylsulfonamide moiety on the 3-position of the indole-2-carboxylic acid scaffold (compounds 22f and 22g) were identified with IC50s at the submicromolar levels. Three X-ray crystal structures of the complexes were solved and revealed the structural basis for the inhibitory activity. The chemoinformatics analysis further disclosed the distinct binding features of this class of inhibitors, providing an insight for further modifications to create structurally distinct FBPase inhibitors with high potency and drug-like properties.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据